Cannabix Technologies Granted Patent from USPTO for Contactless Breath Analysis

Vancouver, British Columbia, October 27, 2025 -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) is pleased to report that the United States Patent and Trademark Office (USPTO) have granted patent No. 18/1729,658 entitled, “Contact-Free Breath Analysis Device and Method” to the Company.

This patent is centered on innovations made by Cannabix and its dual mode contactless (and traditional mouthpiece) breath capture and analysis technology used inside the Company’s BreathLogix device platform and holds the potential for wide-ranging utility. The technology can be integrated into everyday environments such as vehicles, workplaces, or public kiosks, and it supports fast, reliable testing without requiring physical contact. The technology can be used in unmanned breath devices; it offers real-time feedback through visual indicators and displays. The system intelligently adjusts its internal airflow and pump mechanisms based on the sampling method, ensuring accurate and hygienic analysis. Cannabix’s design is compact and modular and well-suited for applications in law enforcement, workplace safety, and public health monitoring. 

Rav Mlait, CEO, stated, “We are very pleased to add this important innovation to our patent portfolio. This patent grant enhances Cannabix’s leadership in the world of breath sampling and detection techniques.”